Argenx, a big player in the biotech market, has witnessed incredibly positive performance recently. The company has offered a strong fight to other contenders like
Amgen in the Autoimmune Diseases market. Their recent data in regards to
Sjögren's rivals that of
J&J and additionally impresses with the patient population for
Vyvgart at an R&D day. Argenx reported a 9% rise in Q2 and speculation suggests the myositis data could add billions in value to the company. With FDA approval for its drug as a new treatment for CIDP (Chronic Inflammatory Demyelinating Polyneuropathy), Argenx has been in the spotlight. There's growing optimism around them for a potential new blockbuster with their antibody drug. Furthermore,
Zai Lab-argenx's efgartigimod alfa has been approved for gMG in China, indicating that Argenx is furthering its geographical presence. For a while, Argenx had to face J&J’s challenge and pull back 23% in Q4, however, it now appears that their strong Q2 Sales have reinvigorated clinical plans for Vyvgart. All these life-altering drug developments point to an optimistic future for Argenx.
argenx News Analytics from Thu, 16 Nov 2023 08:00:00 GMT to Sat, 28 Sep 2024 15:19:36 GMT -
Rating 7
- Innovation 6
- Information 7
- Rumor 5
